SAN DIEGO, CA--(Marketwire - March 12, 2013) - Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, has been invited to present at the ROTH Capital Partners 25th Annual Growth Stock Conference being held on March 17-20, 2013, at The Ritz Carlton in Dana Point, Calif.
Lpath President and CEO Scott Pancoast is scheduled to present on Tuesday, March 19, 2013 at 1:00 p.m. Pacific time, with one-on-one meetings held throughout the day. He will discuss the company's pathway to regulatory approval and commercialization of its novel lipidomics-based therapeutics, as well as its ability to attract support from financial and strategic partners such as Pfizer, J&J, Biogen Idec, and Merck-Serono, as well as the NIH and the Department of Defense.
The presentation will be webcast live at http://www.wsw.com/webcast/roth27/lptn/, which will be available for replay in the investor relations section at www.lpath.com.
For more information about the conference or to schedule a one-on-one meeting with Lpath management, please contact your ROTH representative at 1-800-933-6830 or via e-mail at firstname.lastname@example.org.
About ROTH Capital Partners
ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. and Hong Kong. For more information on ROTH, please visit www.roth.com.
San Diego-based Lpath, Inc., a therapeutic antibody company, is the category leader in lipid-targeted therapeutics. The company's ImmuneY2™ drug-discovery engine has the unique ability to generate monoclonal antibodies that bind to and inhibit bioactive lipids that contribute to disease. The company is developing three drug candidates: iSONEP™ is in a Phase 2 trial for wet AMD; ASONEP™ is in a Phase 2 trial in Renal Cell Carcinoma patients; and Lpathomab is a preclinical drug candidate that holds promise in pain, neurotrauma, and other diseases.